News Room

A collection of press releases, audio content and media clips featuring INFORMS members and their research.

New Research Calls for Transparency in Medicare Advantage Operations
News Release

BALTIMORE, MD, October 8, 2024 – New findings from a team of renowned researchers calls for transparency and rigorous oversight of the U.S. Medicare Advantage (MA) program, the United States’ largest healthcare capitation program.

Read More
Local Craft Beer Consumers Lose Loyalty When Their Favorite Brands are Acquired
News Release

BALTIMORE, MD, October 8, 2024 – Local craft beer consumers don’t seem to like it when their favorite brands are acquired, showing displeasure through spending habits, according to a new study on brand loyalty and craft beers.

Read More
Number of Holiday Shopping Days Continues to Expand, With Sales Expected to Rise Among Frugal Consumers
Media Coverage

If you’re in a retail store in early October and are struck by the sudden appearance of holiday gifts, sales, and decorations, you won’t be imagining it. The holiday shopping season may come earlier than ever this year due to several factors, from a short shopping period between Thanksgiving and Christmas to the distraction of a national election.

Read More

Resoundingly Human Podcast

An audio journey of how data and analytics save lives, save money and solve problems.

Media Contact

Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578

INFORMS in the News

What are you looking for?

Type of Content
Topic
From Testing to Distribution: The Logistics Behind COVID-19 Vaccines

From Testing to Distribution: The Logistics Behind COVID-19 Vaccines

wbur, November 18, 2020

Scientists work at the mAbxience biosimilar monoclonal antibody laboratory plant in Garin, Buenos Aires province, on August 14, 2020, where an experimental coronavirus vaccine will be produced for Latin America. - Argentina will manufacture while Mexico will pack and distribute in Latin America, except of Brazil, the vaccine against COVID-19 developed by the University of Oxford and the AstraZeneca laboratory.

The COVID Cold Chain: How a Vaccine Will Get to You

The COVID Cold Chain: How a Vaccine Will Get to You

Scientific American, November 19, 2020

Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.

U.S.A. is Number One as COVID-19 Deaths Pass Quarter Million

U.S.A. is Number One as COVID-19 Deaths Pass Quarter Million

People's World, November 18, 2020

It’s probably not exactly what President Donald Trump meant when he borrowed the historic jingoistic slogan “America First” for his administration, but since early in the global COVID-19 pandemic, the U.S. has consistently held the Number One spot in coronavirus cases and deaths. It took less than two months for these numbers to grow from 200,000 to a mind-boggling 250,000 now.

Why Trump's Operation Warp Speed is Credited With Helping Face for COVID-19 Vaccine

Why Trump's Operation Warp Speed is Credited With Helping Face for COVID-19 Vaccine

CBC, November 19, 2020

Operation Warp Speed, a Trump administration initiative to manufacture COVID-19 vaccines as fast as possible, should be lauded as a successful endeavour in what has otherwise been a poor effort to deal with the coronavirus, experts say. "No doubt, Operation Warp Speed is a huge success," said Tinglong Dai, associate professor of Operations Management and Business Analytics at Johns Hopkins University Carey Business School in Baltimore.

Vaccine Poses Immense, Unprecedented Distribution Challenges

Vaccine Poses Immense, Unprecedented Distribution Challenges

Manufacturing Net, November 19, 2020

Reports of spiking COVID-19 cases and related fatalities have been met with recent news of extremely promising vaccines developed by Pfizer and Moderna. With the two offerings promising 90 and 95 percent effectiveness against the virus, respectively, attention now turns to mass production and, more importantly, mass distribution. According to Anna Nagurney, Ph.D., Director of the Virtual Center for Supernetworks and professor at the Department of Operations and Information Management at the University of Massachusetts, distribution is where the biggest challenges lie.

Subject Matter Experts in

Supply Chain

View list of experts

Subject Matter Experts in

Healthcare

View list of experts

INFORMS Magazines

OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.

Access OR/MS Today Magazine

Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.

Access Analytics Magazine